Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911116 · ClinicalTrials.gov registry record · Phase 2
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
A Phase 2 study of Uveitis, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02911116 is a Phase 2 study of Uveitis that has completed, run by National Eye Institute (NEI). The registered enrollment target is 8 participants, below the 617-participant average among 19 other Uveitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02911116, a Phase 2 study of Uveitis, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Uveitis is an inflammation of the eye that can cause vision loss. It is treated with medications and sometimes surgery. However, in many people, treatment does not always prevent loss of vision. A new medication, ustekinumab, reduces inflammation in patients with other inflammatory diseases. Therefore, it might be helpful in treatment of uveitis. Objective: To see if ustekinumab is safe and can help people with uveitis. Eligibility: People ages 18 and older with uveitis Design: Participants will be screened with: Medical and eye disease history Physical exam Eye exam: The pupil is dilated with eye drops. A machine scans the back of the eye. Pictures are taken of the inside of the eye. Blood and urine tests Tuberculosis test Participants will have 6 clinic visits over 28 weeks. Visits lasts 2-3 hours and include: * Medical and eye disease history * Physical and eye exams * Blood and urine tests * Fluorescein angiography: A needle guides a thin plastic tube into an arm vein. A dye is injected into the tube. The dye travels through the veins up to the blood vessels in the eyes. A camera takes pictures of the dye as it flows through the blood vessels in the eyes. * Cohort 1 - Ustekinumab injections at Weeks 0, 4, and 8: The injection is under the skin of the upper arm, leg, or abdomen. Participants will have their uveitis monitored and receive standard uveitis care during the study. * Cohort 2 - Ustekinumab injections via intravenous (IV) injection at first visit, followed by a single 90 mg injection of ustekinumab under the skin of the upper arm, leg or abdomen. For the IV injection a needle will be used to guide a thin plastic tube (catheter) into one of the arm veins. The needle will be removed, leaving only the catheter in the vein.
Conditions Studied
Interventions
- DRUG Ustekinumab
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2020-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02911116
The ClinicalTrials.gov registry entry for NCT02911116 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 617-participant average among 19 other Uveitis trials with a reported enrollment target (99% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveitis appearing as the primary indexed condition, and to 1 intervention - of which Ustekinumab is the first listed.
NCT02911116 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02911116 about?
NCT02911116 is a clinical study titled "Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)". Background: Uveitis is an inflammation of the eye that can cause vision loss. It is treated with medications and sometimes surgery. However, in many people, treatment does not always prevent loss of vision. A new medication, ustekinumab, reduces inflammation in patients with other inflammatory dise...
What is the current status of trial NCT02911116?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2017-03-30. Estimated completion is 2020-05-28.
What conditions does trial NCT02911116 study?
This clinical trial studies the following conditions: Uveitis.
What interventions are being tested in trial NCT02911116?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT02911116?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02911116 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
COMPLETED · Phase 2
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
-
Genetics of Uveitis
RECRUITING
-
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.